The Impact of SETD2 on Tumor Microenvironment in Clear Cell RCC
May 12, 2020 08:00pm
By Danielle Ternyila
Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.
Vivek Subbiah, MD, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential to combine tivozanib (Fotivda) with other agents, particularly ipilimumab (Yervoy),as treatment of patients with renal cell carcinoma (RCC).
It is challenging to compare a VEGFR tyrosine kinase inhibitor (TKI) with another VEGFR TKI. This can only be performed in a randomized study, says Subbiah. A single-arm study would show responses, but it would be best to perform this type of analysis in a multi-arm randomized clinical trial.
Subbiah says this is also why it is important that all patients with RCC go on clinical trials. By doing so, investigators could get any idea on real-world outcomes with tivozanib or other treatment options in the landscape.
The combination of tivozanib plus ipilimumab is a great idea, says Subbiah, because the VEGFR TKI has a longer half-life. Preclinical data have also shown that the agent is synergistic with checkpoint blockade.